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Abstract
Background: We aimed to investigate the bone turnover markers in coronary artery disease (CAD) patients
with and without type 2 diabetes (T2DM) in comparison with control subjects without CAD and T2DM.
Methods: This cross-sectional study was performed on 45 subjects undergoing elective heart surgery; either
for coronary artery bypass grafting or for valve surgery. According to angiographic results, participants were
grouped in two groups with CAD (n = 33) and without CAD (n = 12).
The serum levels of osteocalcin (OC), procollagen I aminoterminal propeptide (P1NP) and carboxy-terminal
collagen crosslinks (CTX), as bone turnover markers, as well as serum levels of 25 (OH) vitamin D3, PTH, and
common metabolic factors were analyzed in all participants.
Results: Serum levels of bone markers did not differ in patients with CAD compared to non-CAD subjects.
Regarding metabolic factors, serum levels of FBG had invert correlation with OC in CAD patients (p = 0.004). The data of
subgroup analysis showed serum levels of OC and CTX were statistically significant lower in CAD-DM than CAD-non
DM (p < 0.05). There were not any significant differences in the P1NP levels between groups.
Conclusions: Our data suggest that CTX and OC would be used as suitable bone markers in CAD patients with T2DM.
However, further clinical studies need to establish the role of these markers in CAD patients with diabetes.
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Background
Type 2 diabetes patients are high susceptible to cardiovas-
cular disease, which is attributable to hyperglycemia, oxida-
tive stress, and inflammation [1–3]. Both disorders are
interrelated to other common disorders such as osteopor-
osis. Cross talk among these conditions proposes shared
biological mechanisms, or common risk factors too [4, 5].
Circulating bone turnover markers (BTMs) mirror the
current bone remodeling phase. There is also evidence
that skeleton as an endocrine system has a pivotal role
in regulating energy metabolism via producing BTMs.
Current researches have suggested osteocalcin (OC) as
a non-collagenous protein regulates glucose, lipid and
energy metabolisms as well as bone metabolism [6].
Most researches have focused on the serum levels of
OC in obesity, metabolic disorder and T2DM condi-
tions [7]. Moreover, the close relation of circulating OC
and atherosclerotic plaque calcification was previously
demonstrated. It has been shown that increased
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endothelial progenitor cells carrying OC and monocytes
expressing OC are associated with plaque vulnerability
in patients with early atherosclerosis [8, 9].
Procollagen type 1 N-terminal propeptide (P1NP) is also
another protein which is secreted by osteoblasts during
the collagen type I synthesis. This protein has been taken
into account in the osteoporosis management [10]. The
serum markers of collagen I and III as the N-terminal pro-
peptides of type I and III procollagen (PINP and PIIINP)
have been suggested to serve useful markers of cardiac
collagen turnover [11]. An extracellular matrix predomin-
antly comprises of type I and III collagen and surrounds
cardiac myocytes. Excess myocardial collagen deposition
has been linked to cardiac hypertrophy, myocardial hiber-
nation, myocardial infarction (MI) and congestive heart
failure [11]. Moreover, it has also reported that lower
levels of P1NP are associated with hyperinsulinemia
and hyperglycemia in healthy individuals [12].
C-terminal cross-linked telopeptide of type-I collagen
(CTX) as a bone resorptive marker is produced by osteo-
clasts during bone resorption. There are inconsistent re-
sults about the association of CTX and diabetes. Recently
a meta-analysis diabetes patients reported the serum levels
of OC and CTX were lower in diabetes patients compare
to controls [13]. Moreover, it has been demonstrated CTX
is a predictive factor of an increased carotid intima-media
thickness in the elderly population [14].
However, little is known regarding the association of
BTMs with T2DM and CAD. Hence, we aimed to investi-
gate the BTMs in CAD patients with and without T2DM




The current cross-sectional study included 45 individuals
who underwent an elective heart surgery; either for coron-
ary artery bypass grafting or for valve surgery, between
September 2011 and March 2012 at the Heart hospital
affiliated to Tehran University of Medical Sciences. Ex-
clusion criteria were endocrine disorders, inflammatory
diseases, and history of previous heart attack, malig-
nancies, and known chronic diseases with the exception
of classic risk factors of CAD. The ethics committee of
Endocrinology and Metabolism Research Institute ap-
proved the study protocol. At the time of recruitment, all
participants provided written informed consent to partici-
pate in all stages of the study. Clinical information was
obtained using a standardized health questionnaire, and
a general practitioner performed the physical examination.
Angiography was performed on patients who presented
with cardiac chest pain and a positive exercise test. In all
cases, where luminal stenosis was more than 50 %, the
participants were considered CAD patients.
The diagnosis of type 2 diabetes mellitus (DM) was
carried out and/or confirmed following the American
Diabetes Association criteria, which includes a fasting
blood glucose ≥126 mg/dL on two separate occasions,
random (non-fasting) blood glucose ≥200 mg/dL on two
separate occasions or a blood glucose >200 mg/dL at 2 h
during a standard oral glucose tolerance test [15].
Biochemical measurements
To control the effect of circadian rhythm and food in-
take, all samples were collected from the patients in the
morning at the same time and also patients fasted for
12 h before taking peripheral venous blood. Serum levels
of glucose (FBG), total cholesterol (TC), high-density
lipoprotein (HDL), low-density lipoprotein (LDL), triglycer-
ides (TG), blood urea nitrogen (BUN), creatinine, magne-
sium (Mg), calcium (Ca), and liver tests (ALT, AST) were
measured by enzymatic colorimetric assay [Pars-Asmun
kits, Iran] using an auto analyzer [Hitachi 902, Japan]. Po-
tassium (K) and sodium (Na) were measured by using a
photoelectric flame photometer [ISE].
Serum 25(OH)D was measured by radioimmunoassay
(RIA) (IDS); intra- and inter-assay coefficients of variation
(CV) were 5.2 and 7.5 %, respectively. Intact parathyroid
hormone (PTH) was measured using electrochemilu-
mine assay (Roche). P1NP was measured by quantitative
sandwich enzyme immunoassay technique (intra- and
inter-assay CV was <8 and <10 %) (Causabio). Osteocalcin
(N-MID Osteocalcin, intra- and inter-assay CV was 0.9
and 1.3 %, respectively) and CTX (intra- and inter-assay
CV was <1.6 and <2.2 %, respectively) were measured
using electrochemiluminescence assay (Roche). The elec-
trochemiluminescence assay for OC recognizes a large N-
terminal midfragment in addition to the intact molecule.
Statistical analysis
Data were analyzed using SPSS software, version 16. As
certain data were not normally distributed, including the
OC, HDL, TG, PTH and P1NP levels, log transformation
were applied to correct their normality distribution. The
student t-test and one-way ANOVA were used to com-
pare the differences in serum levels of bone markers in
CAD patients with and without DM and controls. The
non-parametric test was performed for data were not
normality distributed including Cr, Na and Mg levels. A
Pearson correlation was used to determine correlation be-
tween bone marker levels and metabolic factors. A uni-
variate analysis from General Linear Model (GLM) was
used to control confounding variable effects including
age and sex. Numerical variables are reported as the
mean ± standard error or median (IQR) and categorical
variables are presented as number (percentages). In all tests,
the level of significance was set at two-tailed p-values less
than 0.05 (p < 0.05).
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Results
Characteristics of study populations
This study included 45 patients undergoing elective heart
surgery; either for coronary artery bypass grafting or
for valve surgery. The mean age was 60.82 ± 1.46 years
(55 % men). All subjects were considered based on angi-
ography result; CAD patients (n = 33), non-CAD (n = 12).
Twenty four of CAD patients had angiographically con-
firmed 3-vessel stenosis (>50 %). The clinical and biochem-
ical characteristics of study participants are presented in
Table 1.
There were significant differences in mean ages and sex
between CAD and non-CAD subjects (p < 0.05). There
were not significant differences in the levels of total chol-
esterol, triglyceride, HDL, and LDL between two groups.
This might be caused by current statin therapy; around
50 % of CAD patients used statins. Among CAD patients,
15 patients had history of diabetes. Non-CAD patients
(control group) had not history of diabetes. There were no
patients in either group taking anti-osteoporotic drugs,
vitamin K or vitamin D supplementations.
Bone turnover markers and CAD
Serum bone markers were evaluated in both groups; with
and without CAD. No significant differences were ob-
served in the OC and P1NP levels between CAD and
non-CAD groups (p > 0.05). CTX levels were significantly
lower in CAD patients compared to those in non-CAD
patients (p = 0.039). To investigate the influence of sex on
BTMs, all subjects were stratified based on sex. The serum
levels of OC and P1NP did not significantly differ between
men and women (Log OC: 2.78 ± 0.09 vs. 2.84 ± 0.10, re-
spectively, p = 0.68 and Log P1NP: 3.99 ± 0.20 vs. 3.79 ±
0.28 respectively, p = 0.69). But, the CTX levels were lower
in men than women (0.26 ± 0.02 vs. 0.39 ± 0.04, respect-
ively, p = 0.01) (Fig. 1). In univariate model, after adjusting
for age and sex, there was no significant association
between CTX and CAD (p = 0.56).
Serum bone turnover markers and metabolic factors
In all subjects, there were no significant correlation be-
tween bone markers and metabolic factors such as FBG,
TC, TG, HDL and LDL. There was significant inverse cor-
relation between OC and FBG (r = −0.5, p = 0.004) in the
group of patients with CAD. There was also significant
positive correlation between CTX and TG (r = 0.6, p =
0.02) in non-CAD group. In both groups examined, no
correlations were found between levels of bone markers
and other metabolic factors (p > 0.05) (Table 2). To in-
vestigate serum levels of bone markers with respect to
FBG, the CAD patients were stratified according to history
of T2DM; with CAD-DM (n = 15) and CAD-non DM (n
= 18).
The OC levels were significantly lower in patients with
both CAD and DM compared to CAD-non DM patients
(Log OC: 2.52 ± 0.11 vs. 3.07 ± 0.07, respectively, p = 0.001).
The CTX levels were also significantly lower in CAD-
DM patients than those with CAD-non-DM (0.22 ± 0.03
vs. 0.35 ± 0.03, respectively, p = 0.019). However, in pa-
tients with both CAD and DM, we found no significant
differences in mean value of serum P1NP levels compared
with CAD-non DM (Log P1NP: 4.30 ± 0.28 vs. 3.58 ± 0.24,
respectively, p = 0.19) (Fig. 2).
The mean age of CAD-DM group was similar CAD-
nonDM group (63.82 ± 1.81, vs. 62.50 ± 2.12, respectively,







Age- years 63.32 ± 1.44 55.29 ± 2.06 0.01
EF-% 48.10 ± 2.06 50.68 ± 13.46 0.19
Sex (Men)- N(%) 22 (66) 3 (25) 0.002
BMI- Kg/m2 27.79 ± 1.01 27.95 ± 2.91 0.95
FBG- mg/dl 98.68 ± 4.79 96.76 ± 5.22 0.81
Log.TG 4.94 ± 0.08 4.86 ± 0.13 0.63
TC- mg/dl 160.18 ± 8.27 179.50 ± 10.43 0.09
Log.HDL-mg/dl 3.58 ± 0.05 3.66 ± 0.08 0.41
LDL- mg/dl 99.93 ± 7.48 108.46 ± 8.24 0.82
AST- U/L 20.12 ± 1.07 24.61 ± 2.86 0.16
ALT- U/L 21.63 ± 2.20 21.83 ± 2.52 0.95
25(OH)D - nmol/l 59.69 ± 2.41 57.2 ± 4.14 0.61
Log.PTH-pg/ml 3.11 ± 0.08 3.60 ± 0.24 0.08
K- mmol/l 4.50 ± 0.08 5.34 ± 0.97 0.19
Na- mmol/l 144 (4.50) 142 (5.50) 0.01
Ca- mg/dl 10.01 ± 0.59 7.74 ± 0.84 0.04
Mg- mg/dl 2 (0.20) 2.1 (0.55) 0.21
BUN- mg/dl 45.62 ± 4.44 41.68 ± 9.10 0.64
Cr - mg/dl 0.91 (0.35) 0.7 (0.39) 0.38
ALP- Unit/l 78.36 ± 7.54 66.20 ± 11.84 0.39
Log.OC- ng/ml 2.82 ± 0.08 2.84 ± 0.13 0.89
Log.P1NP- pg/ml 3.89 ± 0.19 3.93 ± 0.35 0.93
CTX-ng/ml 0.28 ± 0.02 0.40 ± 0.05 0.039
Statin user- N(%) 17 (51) 1 (8) 0.006
Type 2 diabetes- N(%) 15 (45) - -
Hypertension- N(%) 16 (48) 3 (25) 0.09
Continuous and categorical variables were described as median ± SE and N(%),
respectively. Non-normal or skewed variables were presented as median and
interquartile range (IQR)- Na, Cr, Mg. Student t.test and Mann-Whitney U test
were applied for normal and non-normal distributed variables, respectively
CAD Coronary artery disease, N number, BMI body mass index, FBG fasting blood
glucose, TG triglycerides, TC total cholesterol, HDL high-density lipoprotein
cholesterol, LDL low-density lipoprotein cholesterol, ALT alanine amino
transferase, AST aspartate amino transferase, PTH parathyroid hormone,
K Potassium, Ca Calcium, Mg Magnesium, Na Sodium, OC Osteocalcin,
CTX carboxy-terminal collagen crosslinks, P1NP procollagen I aminoterminal
propeptide, Log Natural logarithm
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p = 0.90). No significant differences in serum 25 (OH)D
levels were found between two groups (58.87 ± 3.20 vs.
61.62 ± 3.37, respectively, p = 0.84). Also, the serum levels
of PTH were not significantly differences in CAD patients
with and without DM (Log PTH: 3.18 ± 0.13 vs. 3.05 ±
0.10, respectively, p = 0.42). Although a number of statin
users was higher in CAD-DM than CAD-nonDM but it
was not statistically significant (5 out of 15, vs. 12 out of
18, respectively, p = 0.056).
To investigate bone marker levels with respect to lipid
profiles, we stratified CAD patients based on using statins;
statin-users and non-users. There were not any significant
differences in the serum levels of bone markers between
two groups (p > 0.05) (Fig. 3).
In univariate model, these statistical significances in
the levels of OC and CTX were consistently observed even
further adjusting for age and sex between CAD-DM and
CAD-nonDM patients (p = 0.011, p = 0.013, respectively).
Discussion
In this study we measured serum levels of OC and P1NP
as bone formation markers and CTX as bone resorption
marker in CAD patients and controls. Our findings showed
similar levels of BTMs in CAD and non-CAD groups.
There are conflicting results regarding BTMs and cardio-
vascular diseases. In a study by Pennisi et al., it was revealed
that patients with serious atherosclerotic involvement of
the carotid and/or femoral artery had decreased OC serum
levels in comparison with controls, while urinary concen-
tration of CTX and serum levels of osteoprotegerin were
not significantly different between these groups [16]. Based
on Poungvarin et al’s study, there was no difference in
case of OC, and CTX values between CAD patients and
healthy individuals [17, 18] which was compatible with
our findings.
Circulating OC levels are stimulated by using anti-
resorptive agents or vitamin D [19]. In our study population
Fig. 1 Serum levels of OC, CTX, and P1NP in male and female. Bar charts show mean ± SE levels of log-OC (a), log-P1NP (b) and CTX (c) in female
and male. Student t-test was used to compare the mean serum levels of bone markers in female and male. OC; osteocalcin, CTX; cross-linked
C-terminal telopeptide, P1NP; procollagen I aminoterminal propeptide, CTX; carboxy-terminal collagen crosslinks. *p-value < 0.05
Table 2 Correlation between bone markers and metabolic factors
Metabolic
factors















r P r p r p R p R p R p r p r p r p
FBG-mg/dl −0.24 0.11 0.21 0.16 −0.02 0.88 0.53 0.06 −0.29 0.33 0.46 0.11 −0.50** 0.004 0.33 0.06 −0.15 0.39
TC-mg/dl −0.15 0.39 −0.01 0.94 0.22 0.17 0.06 0.86 −0.19 0.58 0.16 0.65 −0.18 0.33 −0.02 0.88 0.22 0.22
Log.TG-mg/dl −0.12 0.42 0.09 0.55 0.10 0.49 0.27 0.37 0.32 0.28 0.61* 0.02 −0.29 0.10 0.02 0.89 −0.12 0.50
Log.HDL-mg/dl −0.18 0.25 0.19 0.22 −0.07 0.62 −0.49 0.08 0.18 0.55 −0.31 0.30 −0.15 0.43 0.28 0.14 −0.07 0.69
LDL-mg/dl 0.07 0.63 −0.08 0.58 0.29* 0.049 0.42 0.15 −0.27 0.37 0.41 0.16 −0.05 0.79 −0.01 0.92 0.26 0.16
BUN-mg/dl −0.02 0.90 −0.13 0.41 −0.05 0.74 −0.18 0.71 −0.45 0.13 −0.11 0.72 0.006 0.97 0.08 0.66 −0.02 0.92
Cr-mg/dl 0.06 0.68 −0.14 0.37 −0.04 0.78 −0.12 0.68 −0.49 0.09 −0.17 0.57 0.18 0.33 0.05 0.79 0.05 0.79
BMI-kg/m2 0.09 0.75 −0.08 0.71 0.17 0.42 0.44 0.27 0.04 0.92 0.38 0.35 −0.43 0.11 −0.19 0.48 −0.17 0.53
r Pearson Correlation, p p-value, CAD Coronary artery disease, BMI body mass index, FBG fasting blood glucose, TG triglycerides, TC total cholesterol, HDL high-density
lipoprotein cholesterol, LDL BMD body mass index, Log Natural logarithm
*Correlation is significant at the 0.05 level (2-tailed)
**Correlation is significant at the 0.01 level (2-tailed)
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no patients in either group were taking anti-osteoporotic
drugs, vitamin K intake or vitamin D supplementations.
Based on current studies, it has suggested that circulat-
ing levels of BTMs are changed in relation to glucose or
fat metabolism [20, 21]. We found significant inverse cor-
relation between OC and FBG in CAD patients. Moreover,
it was suggested that circulating OC was inversely associ-
ated with metabolic abnormality indices including hyper-
glycemia, insulin resistance and carotid atherosclerosis
in human studies [22–24]. Based on experimental stud-
ies hyperglycemia reduces bone turnover, in part,
through impairment osteoblast function and suppres-
sion of circulating OC levels [25, 26].
Our data showed no correlation between BTMs and
lipid profile in CAD patients. It might be caused by the
higher percentage of current statin users in the CAD
group. In subgroup analyzing by using stains, serum
levels of bone markers did not significant differ between
CAD statin users and non-users. A systematic review on
statins and bone health in postmenopausal women showed
no significant association between BTMs and using statins
[27]. However, some studies have revealed using statins as-
sociate negatively with BTMs [28]. Zhi-guo and colleges’ in
the study on male patients with osteopenia revealed CTX
significantly reduced in atorvastatin treatment group [28].
We stratified CAD patients to DM and non-DM sub-
groups. As a major finding, our data showed that there
was a significant difference in serum levels of CTX and
OC between CAD patients with and without DM. Our
findings show that both bone markers; OC and CTX de-
creased in patients with CAD-DM compared to CAD-non
DM patients. It is suggested that changes in bone forma-
tion and resorption are not in a state of balance in CAD
patients with diabetes [13].
Fig. 2 Serum levels of bone markers; in non-CAD-non DM patients, CAD-non DM and CAD-DM. Bar charts represent mean ± SE levels of log.OC (a),
log.P1NP (b) and CTX (c) in CAD patients with and without DM, non CAD-non DM patients. One-way analysis of variance and post-hoc test
were used to compare the mean serum levels of bone markers in three groups. OC; osteocalcin, CTX; cross-linked C-terminal telopeptide,
P1NP; procollagen I aminoterminal propeptide, CTX; carboxy-terminal collagen crosslinks. *p-value <0.05, **p-value < 0.01
Fig. 3 Serum levels of OC, CTX, and P1NP in statin and non-statin-users in CAD patients. Bar charts indicate mean ± SE levels of log-OC (a), log-P1NP (b)
and CTX (c) statin and non-statin users in CAD patients. Student t-test was used to compare the mean serum levels of bone markers in two
groups. OC; osteocalcin, CTX; cross-linked C-terminal telopeptide, P1NP; procollagen I aminoterminal propeptide, CTX; carboxy-terminal
collagen crosslinks
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To note, there are few studies that investigate BTMs in
patients with both CAD and DM. However, there is grow-
ing evidence with conflicting results regarding evaluation
of BTMs in CAD or DM and it was implicated that circu-
lating levels of BTM are changed in these conditions.
Bao and colleges’ assessed serum levels of OC in meta-
bolic syndrome (MS) patients [29]. MS as an aggregate
of cardiometabolic risk factors is associated with increased
risk of developing cardiovascular disease and diabetes [30].
They reported low serum levels of OC as a predictor factor
for developing MS in Chines men. Also, serum OC was
independently correlated with coronary atherosclerosis
index. In another study by Ogawa-Furuya and colleges’,
the serum levels of OC in patients with T2DM and abdom-
inal aortic calcification were measured [31]. They described
that the serum uncarboxilate OC levels were lower in CAD
patients compared to control group ever after adjusting
DM. But the levels of carboxylated OC did not differ be-
tween CAD patients and controls. In present study, we
assessed N-MID osteocalcin by using electrochemilumine
assay. In this method, both circulated intact and the
large N-terminal/midregion fragment in serum are
measured.
In term of PINP, we didn’t find any significant differences
in the serum levels of P1NP in CAD patients compared to
controls and also in CAD patients with and without DM.
Some studies have indicated that circulating collagen
metabolites are reliable surrogate in the context of athero-
sclerotic events, while other investigations have showed
contradictory results. For example, Lin an et al., revealed
the PIIINP circulating levels, but no P1NP were signifi-
cantly associated with the CAD severity in patients without
myocardial infraction [11]. Alla et al. reported that P1NP
levels were lower in patients with hypertension and T2DM
as compared to controls [32]. However, we didn’t evaluate
bone markers in diabetic patients with and without CAD.
Our study has some limitations. Firstly, worked on
small sample size could effect on results. Secondly, the
cross-sectional design of our study limits to determine
the mechanism responsible for decrease in OC in CAD-
DM patients. Longitudinal studies are necessary to de-
fine the clinical relevance of bone markers in the patho-
genesis of cardiovascular disease and monitoring of
disease stage. Thirdly, we didn’t assess bone mineral
density in study population. Evaluation of bone status
should be performed to provide more evidence in this
regard.
Conclusion
In conclusion, our data showed the serum levels of OC
and CTX were lower in CAD patients with T2DM. It is
suggesting that OC and CTX might be as suitable bone
markers to evaluate bone statues in patients with both
CAD and T2DM. It is likely the hyperglycemic background
in T2DM patients may lie in the plausible mechanism for
decreasing OC and CTX in CAD patients.
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